Jessica Durk, MD
Radiation Oncology · Indianapolis, INNPI 1891938742
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,050 of the $1,372 with a category attached, or 76.5%. AstraZeneca accounts for 76.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $1,050 and has fallen 94.0% since, to $63 in 2025.
Across 11 payments — averaging $124.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Boston Scientific$178
- Pharmacyclics LLC, An Abbvie Company$35
- Novocure Inc.$24
- Novartis$21
- Accord Healthcare, Inc.$18
- plus $45 from 3 others
What the payments were for
- Consulting fees$1,05077%
- Food & beverage$32223%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $1,050 |
| Boston Scientific | 1 | $178 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $35 |
| Novocure Inc. | 1 | $24 |
| Novartis | 1 | $21 |
| Accord Healthcare, Inc. | 1 | $18 |
| Rigel Pharmaceuticals, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Agios Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$525
- TAGRISSO$525
- EMBOLD Fibered$178
How this compares
$1,372 in reported general payments places this provider in the 65th percentile of 116 radiation oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fentanyl | 11 | $1,198 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 49 | $1,186 |
| Mometasone Furoate | 44 | $629 |
| Tamsulosin Hcl | 37 | $553 |
| Gabapentin | 31 | $335 |
| Oxycodone Hcl | 15 | $285 |
| Fluconazole | 14 | $250 |
| Nystatin | 13 | $140 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Indianapolis
- Michael EatonIndianapolis$11K
- Gordon WatsonIndianapolis$6K
- John CoxIndianapolis$5K
- Peter GarrettIndianapolis$5K
- Garrett JensenIndianapolis$4K
- Alexander YehIndianapolis$3K
- Erin McCammackIndianapolis$2K
- Zachary OaksIndianapolis$2K
- David KimIndianapolis$2K
- Darrel RossIndianapolis$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.